Eflapegrastim
An investigational long-acting granulocyte colony-stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia. The Biologics License Application (BLA) was originally filed in December, 2019. The company has resubmitted the Biologics License Application (BLA) with an expected six-month review for eflapegrastim following remediation of manufacturing deficiencies.
-
Chemotherapy-Induced Neutropenia (RECOVER, ADVANCE)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
-
Same-day dosing
Preclinical
Phase 1
Phase 2
Phase 3
Approved
-
Pediatric patients treated with myelosuppressive chemotherapy
Preclinical
Phase 1
Phase 2
Phase 3
Approved
For more information click here.
Poziotinib
An investigational orally administered, irreversible tyrosine kinase inhibitor (TKI) for the treatment of solid tumors.
- Previously treated EGFR exon 20 insertion mutation positive non-small cell lung cancer (NSCLC)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
- Previously treated HER2 exon 20 insertion mutation positive NSCLC
Preclinical
Phase 1
Phase 2
Phase 3
Approved
-
Treatment naïve EGFR exon 20 insertion mutation positive NSCLC
Preclinical
Phase 1
Phase 2
Phase 3
Approved
- Treatment naïve HER2 exon 20 insertion mutation positive NSCLC
Preclinical
Phase 1
Phase 2
Phase 3
Approved
- Previously first-line osimertinib treated NSCLC with acquired EGFR mutations (Exploratory)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
- Previously treated atypical EGFR or HER2 mutation positive NSCLC (Exploratory)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
-
Patients with EGFR or HER2 activating mutations in advanced malignancies
Preclinical
Phase 1
Phase 2
Phase 3
Approved
For more information click here.
IGN002
An investigational Interferon/CD20 Monoclonal Antibody Fusion Protein